A Phase 1 interventional study of HGP0904 and HGP0608 in Hypertension(HTN), sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-12.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 163rd largest by enrollment of the 186 interventional ones that give a count, is one of 12 that started in 2014, is one of 17 in phase 1, and was the 124th registered.
6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 19 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 12 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
25 studies in Hypertension by Hanmi Pharmaceutical Company Limited: 2 open now, 2 under way, 1 of them phase 3. Of 23 finished, 1 (4%) have results posted.
Among the 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2014, is the only one in phase 1, and was the 8th registered.
Hanmi Pharmaceutical Company Limited’s Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Hanmi Pharmaceutical Company Limited’s 25 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
amlodipine + losartan + chlorthalidone
Drug: HGP0904 · Drug: HGP0608 · Drug: HGP1405
amlodipine
Drug: HGP0904
losartan
Drug: HGP0608
chlorthalidone
Drug: HGP1405
AUClast
AUClast(Area under the curve to the last measurable concentration)
Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
Cmax
Cmax(maxium concentration)
Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
AUCinf
AUCinf(Area under the curve to infinity)
Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
Tmax
Tmax(Time to maximum concentration)
Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
T1/2
T1/2(Terminal elimination half-life),
Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
CL/F
CL/F(Apparent clearance)
Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
Vz/F
Vz/F(Apparent volume of distribution)
Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
Number of Paticipants With Adverse Events
Time frame: 3 months
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 10 | 7 | 8 | 8 |
| Completed | 7 | 7 | 6 | 6 |
| Not completed | 3 | 0 | 2 | 2 |
AUClast(Area under the curve to the last measurable concentration)
| Ratio(Comb/Alone) | HGP0904 | HGP0608 | HGP1405 | EXP3174 |
|---|---|---|---|---|
| AUClast | 1.0360 (0.9958 to 1.0778) | 1.1606 (1.0885 to 1.2375) | 1.0266 (0.9752 to 1.0807) | 1.0902 (1.0350 to 1.1148) |
Cmax(maxium concentration)
Results for this outcome have not been posted.
AUCinf(Area under the curve to infinity)
Results for this outcome have not been posted.
Tmax(Time to maximum concentration)
Results for this outcome have not been posted.
T1/2(Terminal elimination half-life),
Results for this outcome have not been posted.
CL/F(Apparent clearance)
Results for this outcome have not been posted.
Vz/F(Apparent volume of distribution)
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HGP0904 | — | 1/28 (3.6%) | 0/28 (0%) |
| HGP0608 | — | 0/27 (0%) | 0/27 (0%) |
| HGP1405 | — | 0/27 (0%) | 0/27 (0%) |
| HGP0904+HGP0608+HGP1405 | — | 0/28 (0%) | 2/28 (7.1%) |
| Event | HGP0904 | HGP0608 | HGP1405 | HGP0904+HGP0608+HGP1405 |
|---|---|---|---|---|
| MeningitisInfections and infestations | 1/28 | 0/27 | 0/27 | 0/28 |
| Event | HGP0904 | HGP0608 | HGP1405 | HGP0904+HGP0608+HGP1405 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/28 | 0/27 | 0/27 | 2/28 |
| Age, Continuous(years) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Mean | 26.70 ± 4.06 | 26.43 ± 4.89 | 26.00 ± 3.93 | 24.88 ± 4.05 | 26.06 ± 4.07 |
| Sex: Female, Male(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 10 | 7 | 8 | 8 | 33 |
| Region of Enrollment(participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Korea, Republic of | 10 | 7 | 8 | 8 | 33 |
The record gives a start of Aug 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amlodipine · HGP0608 · Losartan
Hanmi Pharmaceutical Company Limited →